Cochlear Limited (CHEOY)
| Market Cap | 6.87B -43.1% |
| Revenue (ttm) | 1.62B +0.2% |
| Net Income | 101.90M -62.1% |
| EPS | 0.78 -62.1% |
| Shares Out | n/a |
| PE Ratio | 67.94 |
| Forward PE | 29.12 |
| Dividend | 1.07 (2.03%) |
| Ex-Dividend Date | Sep 22, 2026 |
| Volume | 200 |
| Open | 52.59 |
| Previous Close | 53.14 |
| Day's Range | 52.59 - 52.89 |
| 52-Week Range | 31.82 - 98.29 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2026 |
About Cochlear
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers cochlear implant systems; replacement sound processors, accessories, and other services; bone conduction systems and replacement sound processors; and recipient support tools. The company also provides Cochlear connected care solutions, such as Cochlear Nucleus SmartNav System; Cochlear Custom Sound Pro Fitting Software; Cochlear Remote Assist; Cochlear Remote Check; and Cochlear Link. It offers its products and ... [Read more]
Financial Performance
In fiscal year 2026, Cochlear's revenue was 2.35 billion, an increase of 0.19% compared to the previous year's 2.34 billion. Earnings were 147.30 million, a decrease of -62.12%.
Financial numbers in AUD Financial StatementsNews
Cochlear Transcript: AGM 2026
FY 2026 brought slower developed-market growth, margin pressure and restructuring costs, while FY 2027 underlying net profit guidance remained AUD 330–350 million. Priorities include adult referral pathways, Nexa adoption and the TICI and drug-eluting electrode pipelines.
Cochlear® Nucleus® Nexa® System Named One of TIME's Best Inventions of 2026
World's first and only smart cochlear implant system 1,* recognized among TIME's most groundbreaking innovations of the year LONE TREE, Colo., Oct. 20, 2026 /PRNewswire/ -- Cochlear Limited (ASX: COH)...
Cochlear Reaches More Than 1 Million Hours of Patient Experience Across Its Fully Implantable Hearing Technology Research Program
SYDNEY--(BUSINESS WIRE)--Cochlear today announced the completion of recruitment for the worldwide pivotal trial program evaluating fully implantable hearing technology. Patients across Cochlear's full...
Cochlear Earnings Call Transcript: H2 2026
Revenue grew 2% to AUD 2.3 billion with underlying net profit of AUD 322 million, as strong Nexa adoption and price increases in developed markets offset lower pricing in China and emerging market headwinds. FY 2027 guidance anticipates low single-digit revenue growth and flat gross margin, with a medium-term focus on margin recovery and market expansion.
Cochlear Annual report: H2 2026
Cochlear has published its H2 2026 annual report on August 17, 2026.
Cochlear Earnings release: H2 2026
Cochlear released its H2 2026 earnings on August 17, 2026, summarizing the period's financial results.
Cochlear Slides: H2 2026
Cochlear has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 17, 2026.
Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants
During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care LONE TREE, Colo., May 29, 2026 /PRNewswire/ -- May is Better Hearing and Speech M...
MED-EL USA Presents Real World Clinical Insights to Support Tailored Hearing Solutions at the 2026 American Cochlear Implant Association Meeting
DURHAM, N.C.--(BUSINESS WIRE)-- #ACIA2026--Hearing implant leader MED-EL USA is announcing two upcoming symposia at CI2026, the annual meeting of the American Cochlear Implant Association (ACIA) in Ch...
Australia's Cochlear crashes 40% after flagging weak demand and Mideast war impact
Cochlear shares crashed nearly 41% on Wednesday in a record daily fall, after the Australian hearing implants maker slashed its forecast for annual earnings, citing weak trading conditions and uncert...
Cochlear Transcript: Trading update
Lower sales and profit are driven by weak demand in developed markets, Middle East disruptions, and China reimbursement changes. Strategic focus remains on medicalizing hearing loss and accelerating growth initiatives, with a wide guidance range reflecting ongoing uncertainty.
Cochlear Earnings release: Trading update
Cochlear released its earnings on April 21, 2026, summarizing the period's financial results.
From airlines to banks: Australian, New Zealand firms feel heat of Gulf crisis
Companies in Australia and New Zealand are beginning to signal the financial strain from the U.S.-Israeli war on Iran, as higher fuel prices stoke inflation, dent business and consumer confidence, and...
Cochlear North America Celebrates International Cochlear Implant Day with Announcement of 2026 Academic Scholarship Recipients
LONE TREE, Colo., Feb. 25, 2026 /PRNewswire/ -- In celebration of International Cochlear Implant Day, Cochlear North America is proud to announce the recipients of the 2026 Cochlear Academic Scholarsh...
Cochlear Earnings Call Transcript: H1 2026
First half results were impacted by the Nexa launch, leading to a 2% revenue decline and 17% net profit margin, with strong second half growth expected. FX headwinds and competitive pressures affected margins and share, but restructuring and growth initiatives are underway.
Cochlear Quarterly report: H1 2026
Cochlear has published its H1 2026 quarterly earnings report on February 12, 2026.
Cochlear Slides: H1 2026
Cochlear has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 12, 2026.
Cochlear Earnings release: H1 2026
Cochlear released its H1 2026 earnings on February 12, 2026, summarizing the period's financial results.
Cochlear Announces Availability of Nucleus Nexa System to US Military Veterans
LONE TREE, Colo., Jan. 8, 2026 /PRNewswire/ -- Cochlear, the global leader in implantable hearing solutions, is proud to announce that the groundbreaking Nucleus® Nexa® System is now available to elig...
MRI 3T Cochlear Implant Market Poised for 9.96% CAGR Growth, North America Leads
Ottawa, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The global MRI 3T cochlear implant market size is calculated at USD 902.78 million in 2025 and is expected to reach around USD 2101.54 million by 2034, growi...
MED-EL Cochlear Implant Becomes First FDA-Approved Option for Children Seven Months and Older
DURHAM, N.C.--(BUSINESS WIRE)-- #FDAapproval--FDA approves expanded indication for MED-EL cochlear implants for children seven months and older with bilateral sensorineural hearing loss.
Cochlear Transcript: AGM 2025
The AGM covered strong financial results, ongoing R&D investment, and board renewal. Shareholders discussed dividends, global expansion, and risks from tariffs and healthcare funding. Voting on all resolutions proceeded smoothly, with results to be released to the ASX.
Cochlear Earnings Call Transcript: H2 2025
Revenue grew 4% year-over-year with strong Cochlear implant and emerging market growth, but services declined 10% due to U.S. consumer hesitancy and a smaller eligible base. The Nexa system launch and continued R&D investment support a positive outlook, though China pricing and U.S. uncertainty remain headwinds.
Cochlear Annual report: H2 2025
Cochlear has published its H2 2025 annual report on August 14, 2025.
Cochlear Slides: H2 2025
Cochlear has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 14, 2025.